Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Vensica Medical Secures $11M for Overactive Bladder Phase 2 Trials
Details : The fund will support the company's mid-stage clinical trials for its revolutionary treatment of overactive bladder using Xeomin (Incobotulinumtoxin A), delivered through a needle-free device.
Brand Name : Xeomin
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 28, 2024
LOOKING FOR A SUPPLIER?